Wall Street analysts expect that The Medicines Company (NASDAQ:MDCO) will report sales of $3.68 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for The Medicines’ earnings, with the highest sales estimate coming in at $9.28 million and the lowest estimate coming in at $1.50 million. The Medicines reported sales of $16.87 million in the same quarter last year, which suggests a negative year over year growth rate of 78.2%. The business is scheduled to report its next quarterly earnings results on Wednesday, October 24th.

According to Zacks, analysts expect that The Medicines will report full year sales of $15.16 million for the current year, with estimates ranging from $12.00 million to $27.66 million. For the next financial year, analysts expect that the business will post sales of $25.39 million, with estimates ranging from $5.10 million to $74.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow The Medicines.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Wednesday, August 1st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.00) by $0.30. The Medicines had a negative return on equity of 394.33% and a negative net margin of 668.93%. The firm had revenue of $1.67 million for the quarter, compared to analysts’ expectations of $7.20 million. During the same period in the previous year, the firm earned ($0.72) earnings per share. The business’s revenue was down 84.6% compared to the same quarter last year.

Several equities analysts have recently issued reports on MDCO shares. BidaskClub cut The Medicines from a “hold” rating to a “sell” rating in a research note on Saturday, September 8th. ValuEngine cut The Medicines from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. Oppenheimer set a $50.00 price target on The Medicines and gave the stock a “buy” rating in a research note on Monday, September 24th. Citigroup upped their price target on The Medicines from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, August 20th. Finally, Zacks Investment Research raised The Medicines from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The Medicines has an average rating of “Buy” and a consensus price target of $52.63.

Shares of MDCO traded down $0.02 during mid-day trading on Wednesday, hitting $26.23. 778,631 shares of the company’s stock traded hands, compared to its average volume of 1,024,604. The company has a debt-to-equity ratio of 31.23, a quick ratio of 2.55 and a current ratio of 2.60. The Medicines has a 1 year low of $24.45 and a 1 year high of $41.57. The stock has a market capitalization of $2.21 billion, a PE ratio of -3.12 and a beta of 0.79.

In related news, CEO Clive Meanwell sold 50,000 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $39.31, for a total value of $1,965,500.00. Following the sale, the chief executive officer now directly owns 352,409 shares of the company’s stock, valued at $13,853,197.79. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.29% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CIBC Asset Management Inc bought a new stake in shares of The Medicines in the 2nd quarter valued at approximately $210,000. NumerixS Investment Technologies Inc purchased a new stake in The Medicines in the 2nd quarter worth approximately $229,000. Xact Kapitalforvaltning AB grew its stake in The Medicines by 28.9% in the 1st quarter. Xact Kapitalforvaltning AB now owns 10,260 shares of the company’s stock worth $338,000 after acquiring an additional 2,300 shares during the period. PNC Financial Services Group Inc. grew its stake in The Medicines by 29.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,545 shares of the company’s stock worth $348,000 after acquiring an additional 2,398 shares during the period. Finally, Ontario Teachers Pension Plan Board purchased a new stake in The Medicines in the 2nd quarter worth approximately $443,000.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

See Also: What is the NASDAQ?

Get a free copy of the Zacks research report on The Medicines (MDCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.